Evidence map›Paper›PMID 31675437›Full record

Trial reportClinical pharmacology and therapeutics2020

Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis.

Stephanie N Liu, Brandon T Gufford, Jessica Bo Li Lu, Lane R Bushman, Peter L Anderson, Richard F Bergstrom, Zeruesenay Desta, Samir K Gupta

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Stephanie N LiuDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Brandon T GuffordDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Jessica Bo Li LuDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Lane R BushmanDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.
Peter L AndersonDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA.
Richard F BergstromDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Zeruesenay DestaDivision of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.
Samir K GuptaDivision of Infectious Diseases, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana, USA.ORCID 0000-0001-6031-8705
Indiana University Indianapolis · USUniversity of Colorado Anschutz Medical Campus · USIndiana University – Purdue University Indianapolis · US

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Indiana University Comprehensive Training in Clinical PharmacologyT32GM008425 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Zeruesenay Desta, Michael Thomas Eadon · 1992 to 2026
$7.7M
CYP2B6 Genetic Variations and Drug InteractionsR01GM078501 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI DESTA, ZERUESENAY · 2007 to 2015
$3.2M
Mechanisms Underlying Stereoselective Bupropion Metabolism and Complex Drug Interactions.R01GM121707 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI DESTA, ZERUESENAY · 2017 to 2020
$1.5M
NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR002529NIGMS NIH HHS R01 GM078501NIGMS NIH HHS R01 GM121707NIGMS NIH HHS T32 GM008425
6 · The paper itself

Abstract

In a randomized, crossover pharmacokinetic study in healthy volunteers (N = 14), a single dose of 2 g probenecid (PRO)-boosted 600 mg tenofovir disoproxil fumarate (TDF)/400 mg emtricitabine (FTC) (test (T) +PRO) was compared with the current on-demand HIV preexposure prophylaxis from the IPERGAY study (a 600 mg TDF/400 mg FTC on day 1 and 300 mg TDF/200 mg FTC on days 2 and 3) (control, C IPERGAY). PRO increased mean single-dose area under the plasma concentration-time curve extrapolated to infinity (AUC

Indexed as

AdolescentAdultAnti-HIV AgentsArea Under CurveCross-Over StudiesDrug InteractionsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHumansLeukocytes, MononuclearMaleMiddle AgedPre-Exposure ProphylaxisProbenecidYoung AdultAnti-HIV AgentsEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationProbenecid

Identifiers

PMID31675437
PMCPMC7703849
OpenAlexW2987506641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.